Cholinergic therapies in Alzheimer's disease

Drugs of the Future

Volumn 24, Issue 4, 1999, Pages 417-424

  Siddiqui, Muhammad F ^a   Levey, Allan I ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 2,8 DIMETHYL 3 METHYLENE 1 OXA 8 AZASPIRO[4.5]DECANE; 3 (2 DIETHYLAMINO 2 METHYLPROPYLAMINO) 6 PHENYL 5 PROPYLPYRIDAZINE; 3 [3 (3 METHOXYPHENYL) 2 PROPYNYLOXYIMINO] 1 AZABICYCLO[2.2.1]HEPTANE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; BESIPIRDINE; CEVIMELINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HUPERZINE A; LINOPIRDINE; METRIFONATE; MILAMELINE; MUSCARINIC AGENT; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINIC AGENT; OTENZEPAD; PD 142505; PHENSERINE; PHYSOSTIGMINE; RIVASTIGMINE; RO 46 5934; TACRINE; TALSACLIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELNACRINE; XANOMELINE;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; NONHUMAN; REVIEW;

EID: 0033036158     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.04.668318     Document Type: Review

References (81)

1. Evans, D.A., Funkenstein, H., Albert, M.S. et al. Prevalence of Alzheimer's disease in a community population of older persons. JAMA 1989, 262: 2551-6.
2. Cummings, J.L., Kaufer, D. Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology 1996, 47: 876-83.
3. Bartus, R.T., Dean, R.L. III, Beer, B., Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217: 408-17.
4. Coyle, J.T., Price, D.L., DeLong, M.R. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983, 219: 1184-90.
5. Whitehouse, P.J., Price, D.L., Strubble, R.G., Clark, A.W., DeLong, M.R. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982, 215: 1237-9.
6. 2 muscarine receptors in the rat brain. Neuroscience 1986, 19: 551-64.
7. Davies, P., Maloney, A.J.F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, 2: 1403.
8. Whitehouse, P.J., Price, D.L., Clark, A.W., Coyle, J.T., DeLong, M.R. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981, 10: 122-6.
9. Drachman, D.A. Memory and cognitive function in man: Does the cholinergic system have a specific role? Neurology 1977, 27: 783-90.
10. Perry, E.K., Tomlinson, B.E., Blessed, G., Bergman, K., Gibson, P.H., Perry, R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978, 2: 1457-9.
11. Terry, R.D., Masliah, E., Salmon, D.P. et al. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30: 572-80.
12. Van Reckum, R., Black, S.E., Conn, D., Clarke, D. Cognition-enhancing drugs in dementia: A guide to the near future. Can J Psychiatry 1997, 42(Suppl. 1): S35-50.
13. Thai, L.J. Cholinomimetic treatment of Alzheimer's disease. Prog Brain Res 1996, 109: 299-309.
14. Cooper, J.R., Bloom, F.E., Roth, R.H. Acetylcholine. In: The Biochemical Basis of Neuropharmacology. Oxford University Press: New York 1996, 194-225.
15. Asthana, S., Raffaele, K.C., Berardi, A. et al. Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine. Alzheimer Dis Assoc Disord 1995, 9: 223-32.
16. Thal, L.J., Schwartz, G., Sano, M. et al. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology 1996, 47: 1389-95.
17. Eagger, S.A., Levy, R., Sahakian, B.J. Tacrine in Alzheimer's Disease. Lancet 1991, 337: 990-2.
18. Farlow, M., Gracon, S.I., Hershey, L.A. et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992, 268: 2523-9.
19. Schneider, L.S. Clinical pharmacology of aminoacridines in Alzheimer's disease. Neurology 1993, 43(Suppl. 4): S64-79.
20. Davis, K.L., Powchik, P. Tacrine. Lancet 1995, 345: 625-30.
21. Kaufer, D.I., Cummings, J.L., Christine, D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study. J Geriatr Psychiatry Neural 1996, 9: 1-6.
22. Knopman, D., Schneider, L., Davis, K. et al. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality. Neurology 1996, 47: 166-77.
23. Geldmacher, D.S. Donepezil (Aricept) therapy for Alzheimer's disease. Compr Ther 1997, 23: 492-3.
24. Rogers, S.L., Doody, R., Mohs, R., Friedhoff, L.T. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: Results of a 30-week phase III trial. Neurology 1996, 46(Suppl.): A217.
25. Zemlan, F.P., Keys, M., Richter, R.W., Strub, R.L. Double-blind placebo-controlled study of velnacrine in Alzheimer's disease. Life Sci 1996, 58: 1823-32.
26. Zemlan, F.P. et al. Velnacrine for the treatment of Alzheimer's disease: A double-blind, placebo-controlled trial. J Neural Transm 1996, 103: 1105-16.
27. Antuono, P.G. et al. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. Arch Intern Med 1995, 155: 1766-72.
28. Hinz, V.C., Grewig, S., Schmidt, B.H. Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos. Neurochem Res 1996, 21: 331-7.
29. Unni, L.K., Womack, C., Hannant, M.E., Becker, R.E. Pharmacokinetics and pharmacodynamics of metrifonate in humans. Meth Find Exp Clin Pharmacol 1994, 16: 285-9.
30. Sramek, J.J., Anand, R., Wardle, T.S., Irwin, P., Hartman, R.D., Cutler, N.R. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci 1996, 58: 1201-7.
31. Zhu, X.D., Giacobini, E. Second generation cholinesterase inhibitor: Effect of (L)-huperzine A on cortical biogenic amines. J Neurosci Res 1995, 41: 828-35.
32. Ved, H.S., Koenig, M.L., Dave, J.R., Doctor, B.P. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. NeuroReport 1997, 8: 963-8.
33. Cheng, D.H., Ren, H., Tang, X.C. Huperzine A, a novel promising acetylcholinesterase inhibitor. NeuroReport 1996, 8: 97-101.
34. Bores, G.M., Huger, F.P., Petko, W. et al. Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1996, 277: 728-38.
35. Harvey, A.L. The pharmacology of galanthamine and its analogues. Pharmacol Ther 1995, 68: 113-28.
36. Iijima, S., Grieg, N.H., Garofalo, P. et al. Phenserine: A physostigmine derivative that is a long acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze. Psychopharmacology 1993, 112: 415-20.
37. Eagger, S.A., Harvey, R.J. Clinical heterogeneity: Responders to cholinergic therapy. Alzheimer Dis Assoc Disord 1995, 9(Suppl. 2): 37-42.
38. Schneider, L.S., Farlow, M.R. Predicting response to cholinesterase inhibitors in Alzheimer's disease. CNS Drugs 1995, 42: 114-24.
39. Poirier, J., Delisle, M-C., Quirion, R. et al. Apolipoprotein epsilon4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc Natl Acad Sci USA 1995, 92: 12260-4.
40. Geula, C., Mesulam, M. Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease. Brain Res 1989, 498: 185-9.
41. Geula, C., Mesulam, M.M. Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord 1995, 9(Suppl. 2): 23-8.
42. Mesulam, M.M., Geula, C., Moran, A. Anatomy of cholinesterase inhibition in Alzheimer's disease: Effect of physostigmine and tetrahydroaminoacridine on plaques and tangles. Ann Neurol 1987, 22: 683-91.
43. Enz, A., Amstutz, R., Boddeke, H., Gmelin, G., Malanowski, J. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease. Prog Brain Res 1993, 98: 431-8.
44. Goyal, R.K. Muscarinic receptor subtypes: Physiology and clinical implications. New Eng J Med 1989, 321: 1022-9.
45. Levey, A.I., Kitt, C.A., Simonds, W.F., Price, D.L., Brann, M.R. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 1991, 11: 3218-26.
46. Jope, R.S., Song, L., Powers, R.E. Cholinergic activation of phosphoinositide signaling is impaired in Alzheimer's disease brain. Neurobiol Aging 1997, 18: 111-20.
47. Winblad, B., Messamore, E., O'Neill, C., Cowburn, R. Biochemical pathology and treatment strategies in Alzheimer's disease: Emphasis on the cholinergic system. Acta Neurol Scand 1993, (Suppl. 149): 4-6.
48. 1 muscarinic agonist xanomeline (LY246708/NNC11-0232). J Pharmacol Exp Ther 1994, 269: 282-9.
49. 1 receptors. J Pharmacol Exp Ther 1994, 269: 271-81.
50. Bodick, N.C., Offen, W.W., Levey, A.I. et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997, 54: 465-73.
51. Bodick, N.C., Offen, W.W., Shannon, H.E. et al. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord 1997, 11(Suppl. 4): S16-22.
52. Reisberg, B., Borenstein, J., Salob, S.P., Ferris, S.H., Franssen, E., Georgotas, A. Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. J Clin Psychiatry 1987, 48 (Suppl. 5): 9-15.
53. Cummings, J.L. The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology 1997, 48(Suppl. 6): S10-6.
54. O'Donnell, B.F., Drachman, D.A., Barnes, H.J., Peterson, K.E., Swearer, J.M., Lew, R.A. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 1992, 5: 45-52.
55. 1 cells. Life Sci 1995, 56: 1024.
56. Nitsch, R.M., Slack, B.E., Wurtman, R.J., Growdon, J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992, 258: 304-7.
57. Giacobini, E. Cholinesterase inhibitors do more than inhibit cholinesterase. In: Alzheimer Disease: From Molecular Biology to Therapy. Becker, R., Giacobini, E. (Eds.). Birkhauser: Boston 1997, 187-204.
58. 2 receptor antagonist AF-DX 116 improves memory. Brain Res 1990, 524: 72-6.
59. 4 muscarinic receptor subtypes in Alzheimer's disease. Synapse 1997, 26: 341-50.
60. 1-agonist xanomeline and four other clinical candidates for Alzheimer's disease. Soc Neurosci 1997, 23: 1751.
61. Rockwood, K., Beattie, L., Eastwood, M.R. et al. A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease. Can J Neurol Sci 1997, 24: 140-5.
62. Van Dyck, C.H., Lin, C.H., Robinson, R. et al. The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer's disease. Psychopharmacology 1997, 132: 217-26.
63. Mesulam, M.M. The systems-level organization of cholinergic innervation in the cerebral cortex and its alterations in Alzheimer's disease. Prog Brain Res 1996, 109: 285-97.
64. Hubbard, J.W., Nordstrom, S.T., Smith, C.P. et al. α-Adrenergic activity and cardiovascular effects of besipirdine HCL (HP 749) and metabolite P 7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther 1997, 281: 337-46.
65. Huff, F.J., Antuono, P.G., Delagandara, J.E. et al. A treatment and withdrawal trial of besipirdine in Alzheimer disease. Alzheimer Dis Assoc Disord 1996, 10: 93-102.
66. Hakansson, L. Mechanism of action of cholinesterase inhibitors in Alzheimer's disease. Acta Neurol Scand 1993, (Suppl. 149): 7-9.
67. 2-Adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat. Psychopharmacology 1996, 124: 347-54.
68. 99mTc-exametazime shown by single photon emission tomography after oral idazoxan in probable Alzheimer-type dementia. Psychopharmacology 1997, 131: 371-8.
69. Giacobini, E. New trends in cholinergic therapy for Alzheimer disease: Nicotinic agonists or cholinesterase inhibitors? Prog Brain Res 1996, 109: 311-23.
70. Court, J., Clementi, F. Distribution of nicotinic subtypes in human brain. Alzheimer Dis Assoc Disord 1995, 9(Suppl. 2): 6-14.
71. Sunderland, T., Molchan, S.E., Little, J.T., Bahro, M., Putnam, K.T., Weingartner, H. Pharmacologic challenges in Alzheimer's disease and normal controls: Cognitive modeling in humans. Alzheimer Dis Assoc Disord 1997, 11 (Suppl. 4): S23-6.
72. Perry, E.K., Perry, R.H., Smith, C.J. et al. Nicotinic receptor abnormalities in Alzheimer's disease and Parkinson's disease. J Neurol Neurosurg Psychiatry 1987, 50: 806-9.
73. Whitehouse, P.J. Cholinergic therapy in dementia. Acta Neurol Scand 1993, (Suppl. 149): 42-5.
74. Lawrence, A.D., Sahakian, B.J. Alzheimerdisease, attention, and the cholinergic system. Alzheimer Dis Assoc Disord 1995, 9(Suppl. 2): 43-9.
75. Kihara, T., Shimohama, S., Sawada, H. et al. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol 1997, 42: 159-63.
76. Van Duijn, C.M., Hofman, A. Relation between nicotine intake and Alzheimer's disease. Br Med J 1991, 302: 1491-4.
77. Graves, A.B., Van Duijn, C.M., Chandra, V. et al. Alcohol and tobacco consumption as risk factors for Alzheimer's disease: A collaborative re-analysis of case-control studies. Int J Epidemiol 1991, 20(Suppl. 2): S48-57.
78. Arneric, S.P., Sullivan, J.P., Decker, M.W. et al. Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties. Alzheimer Dis Assoc Disord 1995, 9(Suppl. 2): 50-61.
79. Sullivan, J.P., Donnelly-Roberts, D., Briggs, C.A. et al. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Ther 1997, 283: 235-46.
80. Decker, M.W., Bannon, A.W., Curson, P. et al. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitve performance in rats and monkeys. J Pharmacol Exp Ther 1997, 283: 247-58.
81. Decker, M.W., Brioni, J.D. Neuronal nicotinic receptors: Potential treatment of Alzheimer's disease with novel cholinergic channel activators. In: Pharmacological Treatment of Alzheimer's Disease. Brioni, J.D., Decker, M.W. (Eds.). Wiley-Liss, Inc.: New York 1997, 433-59.